Literature DB >> 33639376

Identification of pathogens from the upper respiratory tract of adult emergency department patients at high risk for influenza complications in a pre-Sars-CoV-2 environment.

Justin Hardick1, Kathryn Shaw-Saliba2, Breana McBryde2, Charlotte A Gaydos3, Yu-Hsiang Hsieh2, Frank Lovecchio4, Mark Steele5, David Talan6, Richard E Rothman3.   

Abstract

The emergence of SARS-CoV-2 and subsequent COVID-19 pandemic highlights the morbidity and potential disease severity caused by respiratory viruses. To elucidate pathogen prevalence, etiology of coinfections and URIs from symptomatic adult Emergency department patients in a pre-SARS-CoV-2 environment, we evaluated specimens from four geographically diverse Emergency departments in the United States from 2013-2014 utilizing ePlex RP RUO cartridges (Genmark Diagnostics). The overall positivity was 30.1% (241/799), with 6.6% (16/241) coinfections. Noninfluenza pathogens from most to least common were rhinovirus/enterovirus, coronavirus, human metapneumovirus and RSV, respectively. Broad differences in disease prevalence and pathogen distributions were observed across geographic regions; the site with the highest detection rate (for both mono and coinfections) demonstrated the greatest pathogen diversity. A variety of respiratory pathogens and geographic variations in disease prevalence and copathogen type were observed. Further research is required to evaluate the clinical relevance of these findings, especially considering the SARS-CoV-2 pandemic and related questions regarding SARS-CoV-2 disease severity and the presence of co-infections.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coinfections; Emergency department; Influenza; Multiplex diagnostics; Respiratory infections

Mesh:

Year:  2021        PMID: 33639376      PMCID: PMC8107121          DOI: 10.1016/j.diagmicrobio.2021.115352

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  35 in total

Review 1.  Molecular diagnosis of respiratory virus infections.

Authors:  James B Mahony; Astrid Petrich; Marek Smieja
Journal:  Crit Rev Clin Lab Sci       Date:  2011 Sep-Dec       Impact factor: 6.250

2.  The economic burden of non-influenza-related viral respiratory tract infection in the United States.

Authors:  A Mark Fendrick; Arnold S Monto; Brian Nightengale; Matthew Sarnes
Journal:  Arch Intern Med       Date:  2003-02-24

3.  Epidemiologic analysis of respiratory viral infections among Singapore military servicemen in 2016.

Authors:  Yuk-Fai Lau; Wee-Hong Victor Koh; Clement Kan; Poh-Choo Alethea Dua; Ai-Sim Elizabeth Lim; Chin-Wen Jasper Liaw; Qiu-Han Gao; Jeremiah Chng; Vernon J Lee; Boon-Huan Tan; Jin-Phang Loh
Journal:  BMC Infect Dis       Date:  2018-03-12       Impact factor: 3.090

4.  Longitudinal active sampling for respiratory viral infections across age groups.

Authors:  Marta Galanti; Ruthie Birger; Minhaz Ud-Dean; Ioan Filip; Haruka Morita; Devon Comito; Simon Anthony; Greg A Freyer; Sadiat Ibrahim; Benjamin Lane; Chanel Ligon; Raul Rabadan; Atinuke Shittu; Eudosie Tagne; Jeffrey Shaman
Journal:  Influenza Other Respir Viruses       Date:  2019-02-15       Impact factor: 4.380

5.  Impact of bacterial and viral coinfection in community-acquired pneumonia in adults.

Authors:  Yong Kwan Lim; Oh Joo Kweon; Hye Ryoun Kim; Tae-Hyoung Kim; Mi-Kyung Lee
Journal:  Diagn Microbiol Infect Dis       Date:  2018-11-24       Impact factor: 2.803

Review 6.  Critical evaluation of FDA-approved respiratory multiplex assays for public health surveillance.

Authors:  John D Diaz-Decaro; Nicole M Green; Hilary A Godwin
Journal:  Expert Rev Mol Diagn       Date:  2018-06-19       Impact factor: 5.225

Review 7.  Multiplex PCR system for the rapid diagnosis of respiratory virus infection: systematic review and meta-analysis.

Authors:  H-S Huang; C-L Tsai; J Chang; T-C Hsu; S Lin; C-C Lee
Journal:  Clin Microbiol Infect       Date:  2017-12-05       Impact factor: 8.067

8.  Contribution of the FilmArray Respiratory Panel in the management of adult and pediatric patients attending the emergency room during 2015-2016 influenza epidemics: An interventional study.

Authors:  L Busson; M Bartiaux; S Brahim; D Konopnicki; N Dauby; M Gérard; P De Backer; K Van Vaerenbergh; B Mahadeb; L Mekkaoui; M De Foor; M Wautier; O Vandenberg; P Mols; J Levy; M Hallin
Journal:  Int J Infect Dis       Date:  2019-03-26       Impact factor: 3.623

Review 9.  SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences.

Authors:  Melika Lotfi; Nima Rezaei
Journal:  J Med Virol       Date:  2020-06-19       Impact factor: 20.693

10.  Evaluation of FilmArray respiratory panel multiplex polymerase chain reaction assay for detection of pathogens in adult outpatients with acute respiratory tract infection.

Authors:  Norihito Kaku; Kohji Hashiguchi; Yuki Iwanaga; Norihiko Akamatsu; Junichi Matsuda; Kosuke Kosai; Naoki Uno; Yoshitomo Morinaga; Takeshi Kitazaki; Hiroo Hasegawa; Taiga Miyazaki; Masaaki Fukuda; Koichi Izumikawa; Hiroshi Mukae; Katsunori Yanagihara
Journal:  J Infect Chemother       Date:  2018-06-09       Impact factor: 2.211

View more
  2 in total

1.  Evaluating the Increased Burden of Cardiorespiratory Illness Visits to Adult Emergency Departments During Flu and Bronchiolitis Outbreaks in the Pediatric Population: Retrospective Multicentric Time Series Analysis.

Authors:  Benoit Morel; Guillaume Bouleux; Alain Viallon; Maxime Maignan; Luc Provoost; Jean-Christophe Bernadac; Sarah Devidal; Sylvie Pillet; Aymeric Cantais; Olivier Mory
Journal:  JMIR Public Health Surveill       Date:  2022-03-10

2.  Viral co-infections are associated with increased rates of hospitalization in those with influenza.

Authors:  Kerry L Shannon; Valerie O Osula; Kathryn Shaw-Saliba; Justin Hardick; Breana McBryde; Andrea Dugas; Yu-Hsiang Hsieh; Bhakti Hansoti; Richard E Rothman
Journal:  Influenza Other Respir Viruses       Date:  2022-03-18       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.